How the supplier relationship actually works
Most patients assume a clinic's treatment menu reflects the doctor's clinical judgement. In practice, it reflects something more complicated: a negotiation between what the doctor believes and what the supplier has made it commercially sensible to stock.
Aesthetic medicine runs on a distribution model. Companies that manufacture devices and injectables sell through representatives who visit clinics, pitch products, and structure purchasing agreements. The agreements themselves are often reasonable on paper. The pressure is in the architecture around them: minimum order quantities, volume targets, tiered pricing that rewards bulk purchase, and, sitting above all of it, the informal economy of recognition.
Buy enough units and you become a preferred account. Buy more and a title appears: top user, top buyer, KOL, key opinion leader. Conference invitations follow. Your name appears in the company's materials. You are listed as a trainer or an ambassador. To a patient reading your bio, it looks like expertise. Inside the industry, everyone knows what it actually measures.
When the fridge is too full
Here is the mechanism nobody states plainly. When a clinic over-purchases to hit a volume target, or to secure a better price tier, or simply because the sales representative made a persuasive case, the stock sits in a fridge with an expiry date. That date applies pressure.
A practitioner who has bought six months of a product in advance has a quiet incentive to recommend it. Not necessarily through dishonesty. The slide from 'this patient might benefit from this' to 'this patient needs this, and conveniently we have it' is gradual and largely unconscious. The treatment ends up on the recommendation not because the diagnosis called for it, but because the purchase already happened. Supply-led, not diagnosis-led. The supplier incentive reshapes the recommendation without anyone having to decide to be dishonest.
This is what I mean when I say the fridge decides. A clinic carrying ten SKUs of injectables has a structural reason to use all ten. A clinic carrying three has a structural reason to be precise about which three are genuinely indicated. The size of the inventory is itself a clinical signal, though patients have no way to read it.
The KOL economy: badges that are receipts
The awards circuit in aesthetic medicine deserves its own examination. 'Award-winning clinic,' 'top injector,' 'KOL for X brand': these credentials carry real weight with patients searching for reassurance. In many cases they are entirely legitimate. In others, they are a measure of purchase volume dressed as clinical recognition.
I will include myself here, because transparency requires it. I have received conference passes and product recognition from suppliers I genuinely believed in. Those relationships existed because I thought the products were good, not because I was chasing the perks. But I cannot claim the benefit was zero, and I will not. What I can say is that the intent matters, and the intent is not always what drives other corners of this industry.
Some suppliers design their recognition programmes to convert doctors into distribution channels. A doctor who has accepted KOL status, conference billing, and a page in the company's marketing materials is a doctor with a reputational stake in that product's success. The independence of their recommendation has been quietly purchased, even if they do not experience it that way. Patients cannot see the receipt behind the badge.
Where the overbought stock goes
When a clinic cannot move what it over-purchased, the stock has to go somewhere. Some of it is quietly written off. Some of it flows into channels the original purchase agreement never envisioned: cheaper clinics, wellness centres, and, in the cases that end up in the news, operators who are not medical professionals at all.
This is not speculation. It is the supply-side explanation for a problem Malaysian regulators have been trying to address through formal mechanisms. The Medical Device (Amendment) Order 2026 is, among other things, a downstream response to exactly this: procedures and products reaching hands they were never meant to reach, partly because the supply chain upstream had already over-extended. The legal framework closes the tap at the point of practice. The commercial incentives that opened the tap in the first place are a different, and so far quieter, conversation.
Oversupply also drives price compression. When product is abundant and clinics are competing to move it, prices fall. Patients see the discount and read it as a deal. What they cannot see is the margin pressure behind it, and what gets squeezed when margins narrow: the time spent on assessment, the willingness to say a patient does not need a treatment, the capacity to carry fewer SKUs and be selective about what they are.
The complicity I am including myself in
Doctors know this machine exists. Many of us have operated inside it to varying degrees, some without realising it, some with full awareness and a private discomfort we set aside because the alternative was losing supplier relationships, conference invitations, and the path of least resistance.
I have kept my product list tight deliberately. On some products I hold minimal inventory and cannot access volume pricing, which means lower margins on those lines. That is a choice, and it costs something commercially. But it is the only way I know to keep the fridge from deciding the diagnosis. The restraint is structural, not just principled. Principles are easier to override when the supplier representative is standing in your clinic with a compelling offer.
I am not positioning this clinic as the clean exception to a dirty industry. That framing would be self-serving and would miss the point. The point is that the pressure exists systemically, it shapes recommendations in ways that are largely invisible to patients, and most doctors, including me for a long time, have chosen not to name it publicly because naming it has costs. This piece is where that choice ends, at least for me.
How a patient might read the room
There are questions that surface a supply-led recommendation without requiring a patient to become a cynic. They are not accusatory questions. They are the questions a good diagnostic conversation should invite anyway.
Why this treatment for my specific concern? What else was considered and set aside, and why? If you did not currently stock this, would your recommendation be the same? These are not gotcha questions. A practitioner who is genuinely working from diagnosis will answer them without defensiveness, often with relief that the patient is engaged enough to ask.
A practitioner who deflects them, or pivots immediately to a package price, or cannot explain what problem the treatment is solving for this particular face, this particular patient, at this particular point in time: that is information too.
Naming the machine is where the quiet ends. It does not immediately fix it. But a patient who understands how recommendations get made is harder to steer in the wrong direction, and that matters more than any single treatment choice.
